Uremic pruritus and long-term morbidities in the dialysis population

PLoS One. 2020 Oct 26;15(10):e0241088. doi: 10.1371/journal.pone.0241088. eCollection 2020.

Abstract

Background: Uremic pruritus (UP) is a multifactorial problem that contributes to low quality of life in dialysis patients. The long-term influences of UP on dialysis patients are still poorly understood. This study aims to elucidate the contribution of UP to long-term outcomes.

Materials and method: We used the Taiwan National Health Insurance Research Database to conduct this study. Patients on chronic dialysis were included and divided into UP and non-UP groups according to the long-term prescription of antihistamine in the absence of other indications. The outcomes include infection-related hospitalization, catheter-related infection, major adverse cardiac and cerebrovascular events (MACCE) and parathyroidectomy.

Results: After propensity score matching, 14,760 patients with UP and 29,520 patients without UP were eligible for analysis. After a mean follow-up of 5 years, we found that infection-related hospitalization, MACCE, catheter-related infection, heart failure and parathyroidectomy were all slightly higher in the UP than non-UP group (hazard ratio: 1.18 [1.16-1.21], 1.05 [1.01-1.09], 1.16 [1.12-1.21], 1.08 [1.01-1.16] and 1.10 [1.01-1.20], respectively). Subgroup analysis revealed that the increased risk of adverse events by UP was generally more apparent in younger patients and patients who underwent peritoneal dialysis.

Conclusion: UP may be significantly associated with an increased risk of long-term morbidities.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Comorbidity
  • Female
  • Heart Failure / mortality*
  • Humans
  • Infections / mortality*
  • Male
  • Middle Aged
  • Parathyroidectomy / mortality*
  • Pruritus / epidemiology*
  • Renal Dialysis / adverse effects*
  • Risk Factors
  • Taiwan / epidemiology

Grants and funding

This work was supported by Taiwan Ministry of Science and Technology in the form of a grant awarded to CHC (106-2314-B-182A-118-MY3) and Taiwan Clinical Trial Consortium in the form of grants awarded to CHC (MOST 106-2321-B-182-002, 105-2314-B-002-045) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.